Anthem Biosciences Share Price Falls 2.80 Percent as Investors React to Q1 FY27 Results

Anthem Biosciences share price falls 2.80 percent to Rs 769.40. Results announced 21 July 2026. Revenue declined to Rs 418.2 crore from Rs 540.2 crore a year earlier, PAT was Rs 119.9 crore.

Updated: 22 Jul 2026 • 11:31 am

Posted by:

Anthem Biosciences Share Price Falls 2.80 Percent as Investors React to Q1 FY27 Results

The Anthem Biosciences share price falls 2.80 percent in trade on Wednesday, 22 July 2026, as investors continued to react to Anthem Biosciences‘s Q1 FY27 results, announced a day earlier on 21 July 2026. Anthem Biosciences reported Q1 FY27 revenue of Rs 418.2 crore, down from Rs 540.2 crore in the year ago quarter, with net profit of Rs 119.9 crore for the period.

Click Here – Get Free Investment Predictions

Table of Contents

Anthem Biosciences Share Price: Trading Levels Today

Metric	Value
Anthem Biosciences CMP	Rs 769.40
Day Change	Down 2.80 percent
Previous Close	Rs 791.55
Intraday Range	Rs 732.00 to Rs 774.75
Results Announced	21 July 2026 (Q1 FY27)

Learn More About Univest, a SEBI Registered Investment Advisor

Why Anthem Biosciences Share Price Is Reacting This Way

Anthem Biosciences shares fell today as investors reacted to the year on year revenue decline at the CRDMO and specialty ingredients maker, since a shrinking topline is typically read more negatively than a one off margin miss for a growth focused contract research and manufacturing business.

It is worth noting that today’s price move reflects trading on 22 July, the session after the results were announced on 21 July 2026, rather than the immediate results day reaction. Investors comparing the Anthem Biosciences share price move against the results should account for this one day gap when assessing the market’s read on the numbers.

Download the Univest iOS App or Univest Android App to track Anthem Biosciences share price and Q1 FY27 results updates.

Anthem Biosciences Q1 FY27 Results: What This Means for Investors

Revenue for CRDMO businesses can be lumpy quarter to quarter depending on large customer order timing, and investors should watch whether the revenue decline reverses in coming quarters or reflects a more structural slowdown in order flow.

Investors tracking the Anthem Biosciences share price should weigh today’s move alongside management commentary from the post results call, including guidance for the rest of FY27, before drawing firm conclusions from a single session’s trading pattern.

Q1 FY27 Earnings Season: Broader Context

The June 2026 quarter, referred to across Indian markets as Q1 FY27, has seen a heavy cluster of corporate results land within a short window, with dozens of companies across sectors reporting on the same day or within a few sessions of each other. This concentration of results means individual stock reactions can sometimes be influenced as much by broader market mood and sector rotation as by the specific numbers a company reports.

Analysts typically look beyond the headline revenue and profit figures to assess underlying trends such as margin trajectory, working capital movement, and management guidance for the remaining three quarters of the fiscal year. A single quarter of outperformance or underperformance rarely changes a stock’s medium term thesis on its own, which is why many market participants prefer to track two or three consecutive quarters of results before revising their view meaningfully.

Trading volumes and price reactions in the one to two sessions immediately following a results announcement also tend to be more volatile than the trend that eventually settles in over the following weeks, as initial algorithmic and momentum driven trades give way to more considered positioning from longer term investors and institutions.

Retail investors following individual stock reactions during this earnings season are generally better served by comparing each company’s results against its own historical growth trend and sector peers, rather than reacting solely to a single day’s percentage move in isolation, since the initial market reaction can sometimes overshoot or undershoot before settling into a more considered valuation over subsequent sessions.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions

Why did Anthem Biosciences share price falls today?

Ans. Anthem Biosciences share price falls 2.80 percent today as investors reacted to the company’s Q1 FY27 results, which were announced on 21 July 2026.

What is the current Anthem Biosciences share price?

Ans. Anthem Biosciences share price was quoting at Rs 769.40, down 2.80 percent, against a previous close of Rs 791.55.

What did Anthem Biosciences report in its Q1 FY27 results?

Ans. Anthem Biosciences reported Q1 FY27 revenue of Rs 418.2 crore, down from Rs 540.2 crore in the year ago quarter, with net profit of Rs 119.9 crore for the period.

When did Anthem Biosciences announce its Q1 FY27 results?

Ans. Anthem Biosciences announced its Q1 FY27 (June quarter) results on 21 July 2026.

What is the intraday range for Anthem Biosciences share price today?

Ans. Anthem Biosciences share price moved in a range of Rs 732.00 to Rs 774.75 during today’s session.

Is Anthem Biosciences share price a buy after these Q1 results?

Ans. This article does not constitute investment advice. Investors should review the full results and management commentary and consult a SEBI registered investment advisor before investing.